Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sexual Dysfunction, Physiological | 1 | 2025 | 16 | 0.970 |
Why?
|
| Sexuality | 1 | 2025 | 14 | 0.950 |
Why?
|
| Nurse's Role | 1 | 2025 | 70 | 0.940 |
Why?
|
| Neoplasms | 2 | 2025 | 1305 | 0.940 |
Why?
|
| Attitude of Health Personnel | 1 | 2025 | 360 | 0.750 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2025 | 509 | 0.710 |
Why?
|
| Myocardial Infarction | 3 | 2024 | 413 | 0.480 |
Why?
|
| Coronary Artery Disease | 3 | 2024 | 297 | 0.470 |
Why?
|
| Cardiovascular Diseases | 2 | 2023 | 486 | 0.250 |
Why?
|
| Exercise Test | 3 | 2024 | 141 | 0.250 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2024 | 62 | 0.220 |
Why?
|
| Registries | 1 | 2024 | 580 | 0.180 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2024 | 307 | 0.160 |
Why?
|
| Hospitalization | 1 | 2024 | 732 | 0.160 |
Why?
|
| Quality of Life | 1 | 2025 | 868 | 0.160 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2019 | 66 | 0.160 |
Why?
|
| Female | 6 | 2025 | 28105 | 0.160 |
Why?
|
| Hyperthyroidism | 1 | 2019 | 28 | 0.160 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2019 | 58 | 0.160 |
Why?
|
| Male | 5 | 2025 | 26696 | 0.150 |
Why?
|
| Heart Failure | 1 | 2024 | 571 | 0.150 |
Why?
|
| Hypothyroidism | 1 | 2019 | 57 | 0.150 |
Why?
|
| Stroke Volume | 1 | 2019 | 153 | 0.150 |
Why?
|
| Humans | 9 | 2025 | 52336 | 0.140 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 506 | 0.130 |
Why?
|
| Prognosis | 3 | 2024 | 2094 | 0.100 |
Why?
|
| Electrocardiography | 2 | 2024 | 267 | 0.090 |
Why?
|
| Jordan | 2 | 2019 | 8 | 0.080 |
Why?
|
| Risk Factors | 3 | 2023 | 3872 | 0.080 |
Why?
|
| Middle Aged | 4 | 2024 | 13014 | 0.060 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2024 | 30 | 0.060 |
Why?
|
| Enoxaparin | 1 | 2024 | 30 | 0.050 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2024 | 106 | 0.050 |
Why?
|
| Heparin | 1 | 2024 | 88 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 115 | 0.050 |
Why?
|
| Vasodilator Agents | 1 | 2022 | 93 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2024 | 267 | 0.040 |
Why?
|
| Echocardiography | 1 | 2024 | 412 | 0.040 |
Why?
|
| Coronary Angiography | 1 | 2022 | 366 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2024 | 1532 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2022 | 943 | 0.040 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2019 | 18 | 0.040 |
Why?
|
| Myocardial Revascularization | 1 | 2019 | 21 | 0.040 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2019 | 17 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2024 | 2268 | 0.040 |
Why?
|
| Haplotypes | 1 | 2019 | 94 | 0.040 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2019 | 52 | 0.040 |
Why?
|
| Rest | 1 | 2019 | 60 | 0.040 |
Why?
|
| Adenosine | 1 | 2019 | 72 | 0.040 |
Why?
|
| Alleles | 1 | 2019 | 277 | 0.040 |
Why?
|
| Aged | 2 | 2024 | 10109 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2019 | 205 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2019 | 460 | 0.040 |
Why?
|
| Genotype | 1 | 2019 | 569 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 940 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 528 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2019 | 1201 | 0.030 |
Why?
|
| Adult | 2 | 2023 | 14139 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2019 | 592 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2024 | 5407 | 0.030 |
Why?
|
| Young Adult | 1 | 2019 | 4319 | 0.020 |
Why?
|